China Medical System Holdings Limited (HKG:0867)
10.99
-0.21 (-1.88%)
Sep 1, 2026, 4:08 PM HKT
HKG:0867 Revenue
China Medical System Holdings had revenue of 4.50B CNY in the half year ending June 30, 2026, with 24.64% growth. This brings the company's revenue in the last twelve months to 8.71B, up 10.83% year-over-year. In the year 2025, China Medical System Holdings had annual revenue of 8.21B with 9.95% growth.
Revenue (ttm)
8.71B CNY
Revenue Growth
+10.83%
P/S Ratio
2.66
Revenue / Employee
1.36M CNY
Employees
6,415
Market Cap
26.74B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.21B | 743.07M | 9.95% |
| Dec 31, 2024 | 7.47B | -544.30M | -6.79% |
| Dec 31, 2023 | 8.01B | -1.14B | -12.43% |
| Dec 31, 2022 | 9.15B | 813.13M | 9.75% |
| Dec 31, 2021 | 8.34B | 1.39B | 20.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| China Resources Pharmaceutical Group | 314.21B |
| The United Laboratories International Holdings | 14.70B |
| Grand Pharmaceutical Group | 12.48B |
| Simcere Pharmaceutical Group | 10.07B |
| Shandong Xinhua Pharmaceutical Company | 9.78B |
| Luye Pharma Group | 7.02B |
| Sunshine Lake Pharma | 5.36B |
| Consun Pharmaceutical Group | 4.19B |
China Medical System Holdings News
- 1 day ago - China Medical System Licenses Leios' 10XB-101 In China; Plans Strategic Investment - Nasdaq
- 15 days ago - China Medical System Holdings Earnings release: H1 2026 - Filings
- 6 months ago - China Medical System Holdings Annual report: H2 2025 - Filings
- 6 months ago - China Medical System Holdings Earnings release: H2 2025 - Filings
- 6 months ago - China Medical System reports NMPA acceptance of ruxolitinib phosphate cream NDA - TheFly
- 9 months ago - China Medical says povorcitinib included in Breakthrough Therapeutic Drugs list - TheFly
- 9 months ago - CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China - GlobeNewsWire
- 9 months ago - China Medical System announces NMPA acceptance of Y-3 NDA - TheFly